ARO-Lung2
/ Arrowhead Pharmaceuticals
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
December 30, 2020
How Arrowhead Protects Its Intellectual Property
(SeekingAlpha)
- "There's an a-ENaC portfolio with 2 expiry dates, 2028 and 2038, and a b-ENaC portfolio with a 2031 expiry date...ARO-Lung2 is being developed against an undisclosed target as a potential treatment for chronic obstructive pulmonary disorder (COPD). Arrowhead intends to file a clinical trial application at the end of 2020 to begin a Phase 1/2 clinical trial."
New P1/2 trial • Patent • Chronic Obstructive Pulmonary Disease • Cystic Fibrosis • Respiratory Diseases
1 to 1
Of
1
Go to page
1